Currently, there are no FDA approved medications for treatment of
cocaine addiction underscoring the dire need to develop such a product. There is an accumulating body of evidence that l-
tetrahydropalmatine (l-
THP), a non-selective
dopamine antagonist, can be used for the treatment of
cocaine addiction. Indeed, the FDA recently approved its usage in a Phase I study in
cocaine abusers and it was indispensable to develop a simple and sensitive method for the simultaneous determination of l-THP and
cocaine in human plasma. We developed a UPLC-FLD method for quantitation of these molecules using an ACQUITY BEH C18 column (2.1 mm × 50mm, 1.7 μm) and a mobile phase that consisted of 10mM
ammonium phosphate (pH=4.75),
methanol, and
acetonitrile (v:v:v, 78:16:6).
Venlafaxine was used as the internal standard while
hexane was used for the liquid-liquid extraction. The flow rate was 0.4 mL/min with fluorescence detection using an excitation wavelength of 230 nm and emission detection wavelength of 315 nm. This method was selective, linear and sensitive with a lower limit of quantification of 2.5 ng/mL for both
cocaine and l-THP. The intra-day precision of
cocaine and l-THP was <9.50% while the accuracy was <4.29%. The inter-day precision of
cocaine and l-THP was <9.14%, and the accuracy was <12.49%. The recovery for
cocaine and l-THP ranged from 43.95 to 50.02% and 54.65 to 58.31%, respectively. In comparison to forty reported
cocaine quantitation methods this method is simple, sensitive and cost-effective and can be used for simultaneous quantitation of l-THP and
cocaine. This method meets the FDA guidelines and can be used in current and future clinical studies.